



Use of Noninsulin Anti Diabetics for Prevention and Treatment of Cancer- Narrative Review Article

***Sadaf RAANA, Aqeel JAVEED**

Dept. of Pharmacology and Toxicology, University of Veterinary and Animal Sciences, Lahore, Pakistan

***Corresponding Author:** Email: sadaf.sadaf520@gmail.com

(Received 14 Aug 2014; accepted 11 Nov 2014)

Abstract

Background: Epidemiological evidence shows that cancer and diabetes are major causes of death in the world. Type2 diabetes increases the risk of cancer-specific mortality. This review relates diabetic therapies, diabetes and cancer.

Method: All published papers in this field were searched, looking into such databases as Science Direct, ISI Web of Knowledge, PubMed and Scopus.

Results: In cancer patients, metformin improves patient outcome and reduces cancer risk. Sulfonylureas may increase risk of cancer, but decreased risk of cancer is associated with thiazolidinediones in type2 diabetic subjects. Metformin lowers circulating insulin and it may be important for treatment of hyperinsulinemia-associated cancers, such as colon and breast cancer.

Conclusion: However, laboratory investigations and large-scale population based studies are required for further investigation of association of cancer-preventive, anti-cancer and cancer-mortality of noninsulin antidiabetics.

Keywords: Diabetes, Mortality, Metformin hyperinsulinemia, Malignant, Hyperinsulinemia, Thiazolidinediones

Introduction

Epidemiological evidence shows that cancer and diabetes are major causes of death in the world and number of diabetic patients is increasing rapidly (1). A number of studies identified that individuals with diabetes have increased risk of developing several types cancers (2), notably cancers of the pancreas, endometrium, breast, rectum, liver and colon (3, 4)

Hyperinsulinemia, insulin resistance and impaired glucose tolerance might be associated with increased carcinogenesis (5) as up to 80% of pancreatic cancer patients have identified with Diabetes mellitus type 2 or impaired glucose tolerance (6, 7). Influence of anti-diabetic medications on cancer has recently gained attention. Using metformin, an insulin sensitizer, may decrease cancer development, progression, and mortality due to cancer (8,

9). On the other hand, treatment with insulin secretagogues and insulin (sulfonylureas) are related to increased chances of development and mortality related to cancer (10).

Method

In May 2014, all published papers in this field were searched, looking into such databases as Science Direct, ISI Web of Knowledge, PubMed and Scopus. Key words used included antidiabetics and cancer, diabetes and cancer risk and mechanism of antidiabetics drugs in cancer prevention or treatment. All epidemiological and laboratory studies that investigated the effects of antidiabetics on cancer (treatment, prevention and risk) were studied.

Relationship between diabetes and cancer

Type 2 diabetes and malignant tumors have become common diseases worldwide. It is shown by epidemiologic studies that type 2 diabetes increases the risk and tumor specific mortality of some cancers. Endogenous and exogenous hyperinsulinemia have mitogenic effect and may increase the risk of cancer in diabetes (11).

Disturbances of carbohydrate metabolism are commonly observed in cancer patients. Complications of malignant diseases and some medications used in their treatment, such as steroids or parenteral nutrition, may increase blood glucose levels, may affect carbohydrate metabolism, whereas diabetes may hamper oncotherapy (12). A mechanism associated with increased risk of cancer in diabetics is probably by activation of protein kinase Ras/Raf/ (mitogen-activated) pathway along with reduced expression of the growth factor (epidermal) receptor (13). Cancer-associated dysfunction of organ is observed in pancreatic cancer and it may increase insulin dysregulation leading to hyperglycemia and in turn diabetes (14).

Biguanides

Metformin, a biguanide prescribed as first-line antidiabetic in individuals with type 2 diabetes. History of metformin dates back to the use of *Galega officinalis* as botanic medicine for treatment of polyurea in medieval Europe (15, 16). Its glucose-lowering effect is result of decreased glucose production from liver and increased glucose utilization (17). Due to safety, recently metformin has been used for other conditions, for example in treatment and prevention of cancer (18)

Mechanism of metformin action

It acts by targeting enzyme AMPK (AMP activated protein kinase) which is involved in inducing muscles to take up glucose from blood (19). Metformin inhibit proliferation of cancer cell through reducing protein synthesis (20).

Metformin inhibits gluconeogenesis in liver and stimulates uptake of glucose in muscles (21). At cellular level, metformin is involved in regulation of protein kinase activated by AMP (AMPK), activated by elevated level of AMP (intracellular

(22, 23). AMPK (24) is involved in regulating transcription of genes that regulate gluconeogenesis in liver and genes encoding transport of glucose in muscles. As a result, metformin increases sensitivity of insulin and decreases blood glucose (fasting) and level of insulin in diabetic individuals. In a series of in vitro studies evidence for the direct action of metformin on growth of cancer cell has been established. Indeed, metformin exhibits a consistent and strong antiproliferative action on several cancer cell lines with differences in sensitivity of different cancer cell lines (25).

Metformin activates AMPK indirectly by disrupting mitochondrial respiratory chain complex I, leading to decreased ATP synthesis and increase cellular ratio of AMP: ATP (26) this results in stimulation of activity of AMPK. AMP activates AMPK allosterically, facilitating catalytic subunit's phosphorylation by liver kinase B1 (LKB1 which is upstream kinase also called STK11), which is protein product of tumor suppressor gene which is mutated in Peutz-Jeghers cancer predisposition syndrome (27). Dephosphorylation of AMPK Thr172 by protein phosphatases is also prevented by binding of AMP to AMPK. After activation, AMPK cause phosphorylation of many targets as a result a number of catabolic processes are activated for example glycolysis and fatty acid β -oxidation that generates ATP and suppressing many processes, depending on ATP supply by cell, for example synthesis of protein and fatty acid, gluconeogenesis and cholesterol synthesis (28).

Mechanism of action in cancer

Many epidemiological studies show diabetes as a risk factor for cancer. Metformin has been associated with reduced risk of cancer as well as mortalities as compared to other glucose lowering agents. However, interindividual variability of pharmacokinetic parameters in patient response of Metformin is evident (29). Possible anticancer mechanism of noninsulin antidiabetics and their influence is shown in Table 1:

Metformin targets initiating cancer cells. For example, in mice metformin inhibits growth of breast cancer cells in culture and reduces tumor

forming ability (30). According to a study link between AMPK and LKB1 was investigated by deleting LKB1 in livers of mouse (31). This prevented activation of liver-specific AMPK and mice became refractory to glucose lowering action of metformin, demonstrating the primary mechanism of metformin action through active-ting AMPK, p53 a metabolic regulator, depends on AMPK to induce autophagy (32). Activation of AMPK improves survival of stromal cells that are stressed bioenergetically (33).

For energy production cancer cells depend on glycolysis so, adapt a hypoxic environment. For many years, this high rate of glycolysis has been considered as by-product of process of cancer, but evidences suggest that it is required for progression of malignancy (34).

Metformin effects cancer cell metabolism

The mechanism that was demonstrated by Warburg in 1927, called "Warburg effect" describes the observation that the cancer formation takes place due to inefficient cellular respiration. This indicates that even in the presence of oxygen the cancer cells prefer fermentation. Another possible pathophysiological mechanisms related to malignancies is decrease in immune status it has been incriminated as deficient immune system would not be capable to recognize malignant cells (35).

Oxygen consumption is inhibited by metformin in colon cancer cells, and it is consistent with inhibition of oxidative phosphorylation. Metformin is associated with an increased glycolysis in prostate cancer cells (36). All these observations show that metformin inhibits anabolic pathways, decreases cellular metabolism, and induces a stress similar to the metabolic stress. As a result, depending on cell type cellular response varies from autophag, apoptosis, and cell cycle arrest.

Increased IGF-I concentrations

According to hypothesis-increased concentrations of IGF-I increases cancer risk, it increases chances of survival of the cells gathering genetic damages (37) and increases proliferation of cells during the process of stepwise carcinogenesis. There is another possibility (relating insulin levels to poor

outcome) that insulin can stimulate neoplastic behavior of the transformed cells. Insulin-like growth factors and insulin affect chances and risk of cancer (38). MCF-7 cells (breast cancer cell line) are responsive to insulin-like growth factors insulin. Metformin functions as growth inhibitor not as insulin sensitizer for MCF-7 breast cancer cells. Hyperinsulinaemia may also be associated with an accelerated tumor growth through its effect on IGF-1 cancer cell overexpressing insulin and IGF-1 (39). It inhibits mTORC1-pathway by direct and indirect mechanism.

Role in gluconeogenesis and its link to chemoprevention

Metformin inhibits hepatic glucose output by inhibiting gluconeogenesis, leading to decrease in insulin levels (20).

Insulin-dependent effects

The mechanism that supports the association between use of metformin and reduced risk of cancer is found to be same to the mechanism involved in antidiabetic effect. Activation of AMPK Indirectly (via LKB1-dependent mechanism) (40) pathway in skeletal muscles and hepatocytes via metformin leads to lowering of plasma glucose and reducing level of insulin through down regulation of gluconeogenesis regulating genes and stimulating uptake of glucose by muscles (41), both are known to contribute to tumorigenesis. Consequently, metformin shows its action indirectly and reduces negative effects of insulin on progression and growth of tumor and directly inhibits multiplication of cells and colony formation and stimulates partial arrest of cell cycle in cancer cell lines (42).

AMPK-dependent effects

Publication by Shaw et al revealed that AMPK is activated by a gene that is encoding tumor suppressor protein kinase LKB1 (43). LKB1, functions as a tumor suppressor protein and this explains why exercise is beneficial in primary and secondary prevention of certain types of cancers. AMPK is also involved in regulation of genes. Its

activation can suppress expression of lipogenesis-associated genes that are glucose-activated (44).

Breast cancer

Three mechanisms are suggested to define link of diabetes to pathological process of breast cancer, first: activation pathway associated with signaling of insulin, second: activation of pathway of IGFs, third: regulation of sex hormones in body (45, 46). Type 2 diabetics administered pre-operative breast cancer chemotherapy and metformin was presumed to have higher chances of complete remission as compared to the patients not receiving metformin (47). Long-Term use of metformin reduces risk of breast cancer (48). Metformin and doxorubicin culture combination destroys both non-stem cancer cells and cancer stem cells, and decreases tumor mass. That is why combination of chemotherapeutic drugs and metformin improves condition of patients with breast cancer (49).

Metformin reduces breast cancer incidence, reduced colony formation, prognosis (50), and partial arrest of cell cycle at G1 phase leading to improved survival of patients with type 2 diabetes and breast cancer. Metformin's anti-breast cancer activity is due to ability to activate AMP-dependent protein kinase (AMPK) that it is a key regulator of the energy balance in the cells and in whole organism (51).

High level of serum testosterone increases risk of Breast Cancer, particularly in ER-positive Breast Cancer type (52, 53). Reduction of level of testosterone is noticed with Metformin (54). Metformin has shown activity against both estrogen receptor negative (ER) and estrogen receptor positive, when erbB2 breast cancer cell lines were studied. In case of overexpressing erbB2 breast cancer cell lines, Metformin might function in a different way, positively on women who are estrogen-deficient (55) and at elevated concentrations erbB2 expression is decreased, and at low concentrations, it is involved in inhibition of activity of erbB2 tyrosine kinase. These evidences show that metformin might be therapeutically useful against ER negative, ER positive, erbB2 normal and overexpressing cells in breast cancer. Two to three fold elevated risk of PR- and ER-positive breast cancer

was observed in women whose estradiol and testosterone levels were in higher quartiles as compared to women in lower quartile (46).

After menopause androgen is mainly derived from adrenal gland. Main circulating androgen is DHEA (Dehydroepiandrosterone) (56). In adipose tissues DHEAS and its metabolite androstenediol, are converted to delta4 androgens (57). This conversion is major source of circulating testosterone and androstenedione. Ovary produces approximately 25% to 45% of testosterone, 15% of DHEA and androstenedione (58).

Peutz-Jeghers syndrome is associated with Loss of LKB1 function, in which multiple gastrointestinal polyps are formed and significant increased risk (approaching 80%) of different epithelial cancers, for example breast cancer (59).

Prostate Cancer

IGF-I plays role in prostate carcinogenesis (60). Level of IGF-I in body is a heritable trait. Men with higher level of circulating IGF-I are at higher risk of developing prostate cancer (61). Prostate cancer risk is affected by inherited variation in IGF1 (62).

Bladder cancer

In US, bladder cancer is found to be ninth most common malignancy in the world (63). Diabetic patients have an increased risk of developing urinary tract infection, and it has been related to the risk of bladder cancer independent of antidiabetic agents used (64).

In circulation, IGF-I bind to IGF binding protein, IGFBP-3 (65) and may play role in development of prostate, breast, colorectal and bladder cancer. Animal studies support role of IGF-I in tumorigenesis of bladder (66).

Thiazolidinediones

Thiazolidinedione decreases risk of lung, breast and colorectal cancers, and a decreased overall cancer risk. Although limited data is available, it is suggested by some studies that increased risk of bladder cancer is associated with pioglitazone and no increase in risk was observed with rosiglitazone (67-71).

Insulin resistance increases risk of cancer and is reduced by drugs like glitazones and metformin (72).

According to a study, use of pioglitazone in Taiwanese patients having type 2 diabetes mellitus does not influence oral cancer risk, it was suggested that use of pioglitazone had no association with the oral cancer (73).

Complex biological effects are associated with thiazolidinedione peroxisome proliferator activated receptor gamma (PPAR γ) ligands (74) for example growth inhibitory action, but increase in risk of cancer is not predicted by these results (75). PPAR γ related signaling is not involved, in observed urothelial cancer. Crystal formation may lead to chronic bladder irritation in urothelial cancer (76, 77).

Table 1: Possible anticancer mechanism of noninsulin antidiabetics and their influence

Drugs	Possible anticancer mechanism	Influence
Biguanide (Metformin)	<ul style="list-style-type: none"> effects cancer cell metabolism Increased IGF-I concentrations Role in gluconeogenesis and chemoprevention Reduces insulin resistance 	Reduced risk of cancer
Thiazolidinedione	<ul style="list-style-type: none"> Reduces insulin resistance 	Moderately reduced risk of cancer
Sulfonamides	<ul style="list-style-type: none"> Increase level of circulating insulin 	Increased risk of cancer

Sulfonylurea

A recent retrospective study has revealed that sulfonylureas may increase cancer related mortality and cancer risk (78) without exploring differences among individual drugs of sulfonylurea. However, it is still not clear whether increase in cancer-related mortality risk is due to metformin's protective effect or due to unfavorable effect of insulin and sulfonylurea (79). Sulfonylureas stimulate tumorigenesis (80) but the exact mechanisms that relates sulfonylurea to cancer is unknown. According to a hypothesis is sulfonylureas lead to increase in insulin and IGF-1 level and increased activation of insulin receptor, which leads to enhanced risk of cancer. Increase in chances of cancer-associated mortality is studied in diabetic patients given insulin and sulfonylureas in comparison with metformin treated patients. They might be associated with increased risk of thyroid cancer by increasing levels of circulating insulin in body (81).

Conclusion

Insulin is associated with decreases apoptosis and increased proliferation of cells. Diabetes mellitus type 2 patients have a high level of circulating insulin so; have increased chances of developing

cancer as compared with nondiabetic people. In cancer patients, metformin improves patient outcome, Sulfonylureas may increase risk of cancer and modest, but decreased risk of cancer is associated with thiazolidinediones in type2diabetic subjects. Metformin may has a double effect it decrease hyperinsulinemia and hyperglycaemia and at cellular level, inhibiting mTORC1-pathway (cancer supporting) through AMPK- independent and dependent mechanism. Metformin remarkably reduced risks of cancer of breast, colorectum, lungs and liver. Above findings suggest that metformin potentially has an anticancer action.

Use of thiazolidinedione is associated with modest, but reduced risk of lung, breast and colorectal cancers, and a decreased overall cancer risk. However, increased risk of bladder cancer was associated with pioglitazone use. Sulphonylureas may increase cancer related mortality and cancer risk. However, it is still not clear whether increase in cancer-related mortality risk is due to metformin's protective effect or due to unfavorable effect of insulin and sulfonylurea.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or fal-

sification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

The authors declare that there is no conflict of interests.

References

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006). Global and regional burden of disease and risk factors, systematic analysis of population health data. *Lancet*, 367:1747–1757.
2. Arian ER, Pascale F, Anne T, Nies, Elke S, Matthias S (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. *Trends Pharmacol Sci*, 34(2):126–35.
3. Everhart J, Wright D (1995). Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. *JAMA*, 273:1605–1609.
4. El-Serag HB, Hampel H, Javadi F (2006). The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol*, 4:369–380.
5. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, Liu K (2001). Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). *Cancer Causes Control*, 12:763–772.
6. Permert J, Ihse I, Jorfeldt L (1993). Pancreatic cancer is associated with impaired glucose metabolism. *Eur J Surg*, 159: 101–7.
7. Kim YI (1998). Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? *Nutr Rev*, 56:275–279
8. Monami M (2009). Sulphonylureas and cancer: a case-control study. *Acta Diabetol*, 46 (4) pp. 279–284
9. Evans JM (2005). Metformin and reduced risk of cancer in diabetic patients. *BMJ*, 330 (7503) pp. 1304–1305
10. Yang YX, Hennessy S, Lewis JD (2004). Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. *Gastroenterology*, 127(4):1044–50.
11. Rosta A (2011). Diabetes and cancer risk: oncologic considerations. *Orv Hetil*, 17;152-(29):1144–55.
12. Beck E, Scheen AJ (2013). Metformin, an antidiabetic molecule with anti-cancer properties. *Rev Med Liege*, 68(9):444–9.
13. Tseng CH (2011). Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. *Diabetologia*, 54(8):2009–15.
14. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS (2013). Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. *Metabolism: Clinical and Experimental*, 62(7): 922–934
15. Quinn BJ1, Kitagawa H, Memmott RM, Gills JJ, Dennis PA (2013). Repositioning metformin for cancer prevention and treatment. *Trends Endocrinol Metab*, 24(9):469–80.
16. Christos VR, Moses SE (2013). Metformin and cancer. *Eur J Pharmacol*, 13;705(1-3):96–108. Epub 2013 Mar 13.
17. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995). Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. *N Engl J Med*, 333:550–554.
18. Aljada A, Shaker AM (2012). Metformin and neoplasia: implications and indications. *Pharmacology & Therapeutics*, 133(1):108–115.
19. Zakikhani M (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. *Cancer Research*, 66(21):10269–10273.
20. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. (2012). Metformin in cancer: translational challenges. *J Mol Endocrinol*, 48(3):31–43.
21. Cusi K, Consoli A, DeFronzo RA (1996). Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*, 81(11):4059–67.
22. Kahn BB, Alquier T, Carling D, Hardie DG (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab*, 1(1):15–25.
23. Zhou G, Myers R, Li Y, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest*, 108(8):1167–74.
24. Hayashi, T, Hirshman, MF, Kurth, EJ, Winder, WW, Goodyear, LJ (1998). Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. *Diabetes*, 47:1369–1373.

25. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F (2010). Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Mol Cancer Ther*;9:1092-1099.
26. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect-targeted on the respiratory chain complex I. *J Biol Chem*, 275(1):223-8.
27. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci U S A*, 9;101(10):3329-35.
28. Hardie DG (2004). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol*, 8(10):774-85.
29. Rosilio C, Ben-Sahra, Bost F, Peyron JF (2014). Metformin: A metabolic disruptor and anti-diabetic drug to target human leukemia. *Cancer Lett*, 1;346(2):188-96.
30. Dowling RJ, Pamela JG, Vuk S (2011). Understanding the benefit of metformin use in cancer treatment. *BMC Medicine*, 9(1):33.
31. Shaw RJ, Lamia KA, Vasquez D (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science*, 310: 1642-1646.
32. Martin M, Marais R (2012). Metformin: A Diabetes Drug for Cancer, or a Cancer Drug for Diabetics? *J Clin Oncol*, 30(21):2698-700.
33. Jones RG, Plas DR, Kubek S (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. *Mol Cell*, 18:283-93.
34. Fantin VR, St-Pierre J, Leder P (2005). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell*, 9(6):425-34.
35. Mahmood K, Naeem M, Rahimnajiad NA (2013). Metformin: The hidden chronicles of a magic drug. *Eur J Intern Med*, 24(1):20-6.
36. Ben Sahra I, Laurent K, Giuliano S (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. *Cancer Res*, 70:2465-75.
37. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J (1996). Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. *J Clin Invest*, 98: 2612-5.
38. Michael N Pollak (2007). Insulin, insulin-like growth factors, insulin resistance, and neoplasia. *Am J Clin Nutr*; 86(3):s820-2.
39. Seewoodhary J, Stephen CB (2011). Diabetes, diabetes therapies and cancer: what's the link? *Br J Diabetes Vasc Dis*, 11(5):235-238.
40. Libby G, Donnelly LA, Donnan PT et al. (2009). Evans New users of metformin are at low risk of incident cancer. *Diabetes Care*, 32:1620-1625
41. Towler MC, Hardie DG (2007). AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling. *Circulation Research*, 100(3):328-41.
42. Alimova IN (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. *Cell Cycle*, 8 (6):909-915.
43. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC (2003). Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. *J Clin Endocrinol Metab*, 88(3):1323-32.
44. Rosilio C, Lounnas N, Nebout M et al. (2013). The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. *Cancer Lett*, 9;336(1):114-26.
45. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011). Clinical pharmacokinetics of metformin. *Clin Pharmacokinet*, 50(2):81-98.
46. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005). Diabetes mellitus and breast cancer. *Lancet Oncol*, 6:103-11.
47. Jiralspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *AM J Clin Oncol*, 27(20):3297-302.
48. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR (2010). Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer. *Diabetes Care*, 33(6):1304-8.
49. Hirsch HA, Iliopoulos D, Tschlis PN, Struhl K (2009). Metformin selectively targets cancer stem

- cells, and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res*, 69:7507-7511.
50. Campagnoli C, Berrino F, Venturelli E et al. (2013). Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. *Clin Breast Cancer*, 13(6):433-8.
 51. B. Martín-Castillo A, Vázquez-Martín C, Oliveras-Ferraro JA (2010). Menéndez. Metformin: a pharmacological approach integrating hyperinsulinemia breast cancer at the molecular, cellular clinical levels. *Avances en Diabetología*, 26(2):79-94.
 52. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauley (2005). Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. *J. A. Cancer Epidemiol Biomarkers Prev*, 14(5):1047-51.
 53. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004). Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. *J Natl Cancer Inst*, 96(24):1856-65.
 54. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D (2012). Metformin use is associated with better survival of diabetic patients with pancreatic cancer. *Clin Cancer Res*, 18(10):2905-12.
 55. Gordon GG, Olivo J, Rafil F, Southren AL (1975). Conversion of androgens to estrogens in cirrhosis of the liver. *J Clin Endocrinol Metab*, 40(6):1018-1026.
 56. Key TJ, Appleby PN, Reeves GK (2011). Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. *Br J Cancer*, 105:709-722.
 57. Blouin K, Nadeau M, Mailloux J (2009). Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis. *Am J Physiol Endocrinol Metab*, 296:244-255.
 58. Fogle RH, Stanczyk FZ, Zhang X (2007). Ovarian androgen production in postmenopausal women. *J Clin Endocrinol Metab*, 92:3040-3043.
 59. Giardiello FM, Brensinger JD, Tersmette AC (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology*, 119:1447-53.
 60. Cheng I, Stram DO, Penney KL et al. (2009). Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. *J Natl Cancer Inst*, 98(2):123-34.
 61. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M (2007). Insulin like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. *J Natl Cancer Inst*, 94:1099-106.
 62. Wright JL, Stanford JL (2007). Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes Control*, 20(9):1617-22.
 63. Jemal A, Murray T, Ward E (2005). Cancer statistics. *CA Cancer J Clin*, 55:10-30.
 64. Kravchick S, Gal R, Cytron S (2001). Increased incidence of diabetes mellitus in the patients with transitional cell carcinoma of urinary bladder. *Pathol Oncol Res*, 7:56-59.
 65. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X (2003). Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. *J Urol*, 169:714-717.
 66. Larsson SC, Orsini N, Brismar K, Wolk A (*Diabetologia*). Diabetes mellitus and risk of bladder cancer: a meta-analysis. *Diabetologia* HYPERLINK "<http://www.ncbi.nlm.nih.gov/pubmed/17021919>", 49(12):2819-23. Epub 2006 Oct 5.
 67. Azoulay L (2012). The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. *BMJ*, 2012 May 30;344:e3645. doi: 10.1136/bmj.e3645.
 68. Colmers IN, Bowker SL, Johnson JA (2012). Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Metab*, 38(6):475-84.
 69. Vigneri R, Pezzino V, Wong KY, Goldfine ID (1982). Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells. *J Clin Endocrinol Metab*, 54(1):95-100.
 70. Piccinni C, Motola D, Marchesini G (2011). Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. *Diabetes Care*, 34(6):1369-71.
 71. Lewis JD, Ferrara A, Peng T, Hedderston M, Bilker WB, Quesenberry CP Jr (2011). Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. *Diabetes Care*, 34:916.
 72. Garmendia ML, Pereira A, Alvarado ME, Atalah E (2007). Relation between insulin resistance and

- breast cancer among Chilean women. *Ann Epidemiol*, 17:403–409.
73. Tseng CH (2014). Pioglitazone and oral cancer risk in patients with type 2 diabetes. *Oral Oncol*, 50(2):98-103.
74. Kahn BB, McGraw TE (2010). Rosiglitazone, PPARgamma, and type 2 diabetes. *N Engl J Med*, 363:2667-9.
75. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD (1999). Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. *Neoplasia*, 1:330.
76. Sato K, Awasaki Y, Kandori H, Tanakamaru ZY, Nagai H, Baron D (2011). Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. *Toxicol Appl Pharmacol*, 251:234-44.
77. Tseng C-H (2012) Thyroid Cancer Risk Is Not Increased in Diabetic Patients. *PLoS ONE* 7(12): e53096.
78. Yeung Li D, Hassan SC, Konopleva MM, Abbruzzese M (2009). Antidiabetic therapies affect risk of pancreatic cancer. *JL Gastroenterology*, 137(2):482-8.
79. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care*, 2006; 29:254–8.
80. Yang X (2010). Use of sulphonylurea and cancer in type 2 diabetes—the Hong Kong Diabetes Registry. *Diabetes Res Clin Pract*, 90 (3):343–351.
81. Soranna D, Scotti L, Zambon A et al. (2012). Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. *Oncologist*, 17(6):813-22.